INTRODUCTION
Prostate cancer (PCa), which is the most frequently diagnosed cancer of the male urinary system, poses a great threat to the health of older adults in China. 1 Radical prostatectomy (RP) is the standard surgical treatment for localized PCa, 2, 3 and locally advanced PCa is treated using multimodal therapy. 4 The available method used to assess PCa is unable to distinguish micrometastasis from residual, localized regional disease, and medical centers differ in their selection of treatment. 5 However, the major challenges in developing an effective treatment for PCa are the selection of the optimum timing and regimen for treatment as well as the reduction of possible over-treatment. Therefore, an accurate cancer risk assessment method is essential to benefit patients with PCa. 6 We previously found that locus-specific demethylation of CpG dinucleotides within the collapsin response mediator protein 4 (CRMP4) promoter in metastatic prostate cancer cells suppresses metastasis, while locus-specific methylation of CpG dinucleotides of the CRMP4 promoter in nonmetastatic prostate cancer cells promotes metastasis. 7, 8 Therefore, quantitation of CRMP4 methylation levels accurately predicts lymph node (LN) metastasis. 7, 8 The Cancer of the
ORIGINAL ARTICLE
Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients and ADT from October 2000 to December 2015. The relevant characteristics of the 305 patients are as follows: 230 patients with high-risk PCa, according to the D' Amico risk stratification scheme (clinical stage ≥T2c or Gleason score ≥8 or PSA >20 ng ml −1 ), had positive surgical margins or PT3-4N0-1M0. 13, 14 These patients underwent immediate ADT (within 3 months after surgery regardless of postoperative serum PSA levels). Seventy-five patients with intermediate risk (PSA <20 ng ml −1 , clinical stage <T2c, PT2N0M0, and negative surgical margin) 15, 16 PCa underwent deferred ADT (after two consecutive serum PSA values = 0.2 μg l −1 , or those whose disease progression was confirmed by radiological examination or core biopsy after LRP) ( Table 1) .
Surgical techniques
RP was performed by a senior urological surgeon and team who had performed more than 1000 LRP procedures. The details of the surgical techniques were previously described. 17, 18 Pathologic evaluation, tumor grading, and disease staging The 1997 system that staged PCa according to tumor, node, and metastasis (TNM) was used to evaluate patients treated before 2002. The American Joint Committee on Cancer and 2002 TNM staging systems were used to evaluate patients treated after 2002. A positive surgical margin was defined as the presence of tumor tissue on the inked surface of the specimen, accompanied by the patients' outcomes noted in the original pathology reports. 
Follow-up
Follow-up examinations were performed every 3 months during the 1 st year after surgery, every 6 months during the 2 nd year, and annually thereafter. Follow-up examinations included a consultation, digital rectum examination, serum PSA level, cancer progression status, and survival. BCR was defined as two consecutive serum PSA values ≥0.2 μg l −1 after LRP. 20 Clinical progression was defined as localized recurrence or systemic metastatic lesion verified using biopsy tissue or imaging techniques. Recurrence in the deferred ADT group was defined by the presence of BCR or clinical progression. cancer-specifc mortality (CSM) was defined as death caused by prostate cancer or cancer-related death.
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Bisulfite pyrosequencing Genomic DNA extracted from formalin-fixed paraffine mb e d d e d s ampl e s w a s qu ant i f i e d u s i ng a N D -2 0 0 0 spectrophotometer (Nano-Drop Technologies, Thermo Fisher Scientific Inc., Waltham, MA, USA) and modified using an EpiTect Bisulfite Kit (Cat. No. 59104, Qiagen, Hilden, Germany). Bisulfite conversion was performed using thermal cycling conditions. After DNA was converted and depurinated, PCR was performed using a PyroMark PCR kit (Cat. No. 978703, Qiagen, Hilden, Germany) at the recommended cycling conditions, and the amplified DNA was subsequently confirmed. A standard pyrosequencing sample preparation protocol was applied. 22 We used a Biotage Q96 Vacuum Workstation to separate, denature, and wash the amplicons, which were then mixed with the pyrosequencing primers in annealing buffer. PyroGold reagents were used for the pyrosequencing reaction at room temperature after primer annealing, and the signal was analyzed using a PSQ 96MA system (Biotage, Uppsala, Sweden). Target CGs were evaluated using software (PSQ96MA 2.1) included with the instrument, which converted the programs into the numerical values of the peak heights and calculated the proportion of methylation at each base, represented as the C/T ratio. The average C/T ratio of the two CpG sites (upstream target start sites −848 and −841) was defined as the final CRMP4 methylation score of a sample. Our previous study suggests that CRMP4 promoter hypermethylation (≥15.0% methylated) is significantly associated with the development of LN metastasis (P < 0.001). 23 The primers used in this study are listed in Table 2 .
CAPRA-S score
The CAPRA-S score was determined according to the preoperative PSA level, pathological Gleason score (pGS), surgical margin (SM), presence or absence of extracapsular extension, seminal vesicle invasion (SVI), and LN involvement (LNI). Patients who did not undergo lymphadenectomy were assumed not to have LNI. CAPRA-S scores were dichotomized according to the cutoff values (≥6 and <6) of a previously reported high-risk group.
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Statistical analysis
The data were analyzed using Statistical Product and Service Solutions 19.0 software (SPSS Inc., Chicago, IL, USA). The data are presented as the mean ± standard deviation. The t-test was employed to compare groups,  2 test was employed to compare data, and The combination of CAPRA-S score ≥6 and CRMP4 methylation levels ≥15% predicted rates as 84.9%, 60.0%, and 85.0% for 3-year PFS, 5-year PFS, and 5-year CSS, respectively. The combination of CAPRA-S score ≥6 and CRMP4 methylation levels <15% or CAPRA-S score <6 and CRMP4 methylation levels ≥15% predicted rates as 93.6%, 70.4%, and 92.9% for 3-year PFS, 5-year PFS, and 5-year CSS, respectively. Further, CAPRA-S score <6 and CRMP4 methylation levels <15% predicted rates as 100%, 96.9%, and 100% for 3-year PFS, 5-year PFS, and 5-year CSS rates, respectively. The differences in PFS rates between each combination were statistically significant (P < 0.05). The differences in the CSS rates between the combination of CRMP4 methylation levels ≥15% with CAPRA-S score ≥6 and the combination of CAPRA-S score <6 with CRMP4 methylation levels <15% were statistically significant (P < 0.001). In contrast, the differences between the other two comparisons were not statistically significant (Figure 2 ). CRMP4 methylation levels and CAPRA-S score had the highest AUC values for tumor progression as follows: AUC = 0.814 (95% CI: 0.757-0.870) and AUC = 0.804 (95% CI: 0.743-0.864), respectively. The combined model including CRMP4 methylation levels and CAPRA-S score with AUC = 0.854 (95% CI: 0.806-0.902) was an improved predictor of tumor progression compared with a model employing CRMP4 methylation levels (P = 0.0445) or CAPRA-S score (P = 0.0122). The combination of CRMP4 methylation levels and CAPRA-S score was an improved predictor of tumor progression. The AUC value for the combinations (AUC = 0.842 [95% CI: 0.789-0.887]) associated with CSM was higher compared with that Fisher's exact test was employed when the minimum frequency = 0. Progression-free survival (PFS) and cancer-specific survival (CSS) were the primary indexes used for this analysis. The association between CRMP4 methylation levels and the CAPRA-S score with PFS and CSS was assessed using uni-and multi-variable Cox proportional hazards models after adjusting for high-risk clinical parameters as follows: preoperative PSA, biopsy Gleason score, LN status, and seminal vesicle (SV) status. 12 Survival was analyzed using Kaplan-Meier method. Differences between groups were assessed using the log-rank test. Receiver operating characteristic (ROC) curves were generated to evaluate the performance of each risk model, and the area under the curve (AUC) was calculated to estimate the power of each model to predict tumor progression and CSM. All P values are two sided and those <0.05 were considered statistically significant.
RESULTS
After the surgery, 230 (75.4%) patients received immediate ADT and 75 (24.6%) patients first received deferred ADT after a median follow-up of 2.1 years. The average ages of the immediate and deferred ADT groups were 67.3 years (range: 57.8-74.8 years) and 66.5 years (range: 59.6-73.4 years), respectively. The median follow-up time for the immediate and deferred ADT groups was 62 months (range: 11-94 months) and 61 months (range: 25-92 months), respectively. The median exposure time of the immediate and deferred ADT groups to ADT was 36 months and 21 months, respectively. Other clinical data are presented in Table 1 .
Uni-and multi-variable analyses revealed that CRMP4 methylation levels, CAPRA-S, preoperative PSA, biopsy Gleason score, LN status, and SV status were significant independent predictors of PFS and CSS (Figure 1a and 1b) . For CRMP4 methylation levels ≥15%, the hazard ratios (HRs) for tumor progression and CSM were 3.24 (95% CI: 2.01-5.23, P < 0.001) and 6.29 (95% CI: 2.67-14.80, P < 0.001), respectively. For CAPRA-S score ≥6, the HRs for tumor progression and CSM were 7.44 (95% CI: 4.61-12.01, P < 0.001) and Survival analysis of the immediate androgen deprivation therapy group. Subgroups 1, 2, and 3 had CAPRA-S score <6 and CRMP4 methylation levels <15%; CAPRA-S score ≥6 or CRMP4 methylation levels ≥15%, and CAPRA-S score ≥6 and CRMP4 methylation levels ≥15%, respectively. (a) The difference in the PFS rate between each combination was statistically significant (P < 0.05). (b) The differences in CSS rates between Groups 1 and 3 were statistically significant (P < 0.001). The differences between Groups 2 and 1 and between Groups 2 and 3 were not significant. CI: confidence interval; CRMP4: collapsin response mediator protein 4; CRPRA-S: Cancer of the Prostate Risk Assessment Postsurgical score; PFS: progression-free survival; CSS: cancer-specific survival. (Figure 2a and 2b) .
In the deferred ADT group with CRMP4 methylation levels ≥15%, the HRs for tumor progression and with CSM as a continuous variable were 6.81 (95% CI: 2.34-19.80, P < 0.001) and 12.83 (95% CI: 2.16-26.10, P = 0.0026), respectively, indicating that CRMP4 methylation levels ≥15% were a significant independent factor associated with a poor prognosis of patients with intermediate-risk (Figure 2c and 2d) . We were unable to conduct an analysis of CAPRA-S score of the deferred ADT group because CAPRA-S score was ≤6 for most patients and CAPRA-S score alone was insufficient to identify patients with a high risk of poor prognosis.
DISCUSSION
The natural history of PCa can differ significantly; for example, these tumors may not progress or cause symptoms, or the cells can acquire a highly invasive phenotype that metastasizes rapidly and causes death. 24 Localized PCa responded well to most current treatments although the risk for recurrence increased when locally advanced PCa was treated using monotherapy. 25 The choice of treatment for locally advanced PCa is, therefore, a significant clinical issue.
Adjuvant radiotherapy (AT) is considered the optimum treatment for patients with stage-pT3 PCa after undergoing RP. [26] [27] [28] [29] [30] In our institution, at least 100 patients who received AT experienced disease recurrence. However, investigators at other institutions found that numerous patients with stage-pT3 disease did not receive radiotherapy after RP. 29 Slow recovery from urinary incontinence or other long-term urinary complications, including bladder neck contracture and bowel symptoms, occurred during or after AT. [30] [31] [32] The application of radiotherapy to Chinese patients with PCa is not universal and has not been fully developed as the optimum therapy. However, the requirement for adjuvant hormone therapy (AHT) after RP is controversial.
The data published by the Veterans Administration Cooperative Urological Research Group indicated that immediate ADT to treat aggressive cancer may be beneficial for delaying disease progression and increasing the survival rate. 33 For patients with PSA relapse as their only sign of early disease recurrence, it is difficult to distinguish between local and distant recurrence, which may complicate the optimal selection of an early treatment regimen. 34 An adjuvant ADT applied as early as possible that may benefit patients, which conforms to the guidelines on the treatment options for PSA relapse following local treatment, is described in the updated EAU Guidelines on Prostate Cancer. 35 An accurate assessment of the risk of disease progression risk and detection of early, and localized metastatic cancer may confer further comprehensive benefits upon patients who undergo individualized ADT.
The ability of CAPRA-S score to predict disease recurrence and CSM was validated by a multi-institutional study of a diverse sociodemographic clinical population. 11, 12 Our previous studies found Further analysis of the deferred ADT group was not performed because most patients had CAPRA-S score ≤6, negative LN status, negative SV status, and PSA <20 µg l −1 . HR: hazard ratio; CI: confidence interval; ADT: androgen deprivation therapy; PSA: prostate-specific antigen; GS: Gleason score; SV: seminal vesicle; LN: lymph node; CRMP4: collapsin response mediator protein 4; CRPRA-S: Cancer of the Prostate Risk Assessment Postsurgical score that methylation of CpG sites within the CRMP4 promoter region played a key role in the downregulation of CRMP4 expression in metastatic prostate cancer, strongly indicating that the CRMP4 CpG methylation status can be used as an independent marker for early diagnosis of metastatic prostate cancer. 7, 8 Two CpG sites primarily contributed to reducing the transcriptional activities of the CRMP4 promoter, which were determined using bisulfite sequencing, were therefore selected for PCR and Pyrosequencing analyses. ROC curve analysis showed that the discriminative ability to determine prognosis was 100% accurate using the cutoff value of 15.0%. 19 We conclude therefore that integrating CRMP4 methylation levels into clinical practice for individualized patient risk prediction models can significantly improve the management of patients with highly advanced prostate cancer.
In our center, certain high-risk patients with PCa of positive surgical margins or of stage PT3-4N0-1M0, who refused radiotherapy, were treated with ADT within 3 months after surgery and achieved satisfactory overall tumor control. These findings are consistent with those of other studies. [36] [37] [38] [39] [40] For patients in immediate ADT group with CAPRA-S score <6 and CRMP4 methylation levels <15%, low tumor progression rates, and CSM, we believe it is reasonable to perform only postoperative follow-up examinations to avoid over-treatment. CAPRA-S score ≥6 and CRMP4 methylation levels ≥15% would be expected to be associated with a poor outcome. Therefore, early ADT benefitted patients by delaying cancer progression, improving overall survival (OS), and ensuring improved outcomes of cancer control. CAPRA-S score ≥6 and CRMP4 methylation levels ≥15 are variables significantly associated with a poor prognosis. If CAPRA-S score or CRMP4 methylation levels exceed the threshold, we believe that to select a method that comprehensively discriminates between patients' outcomes, the timing of adjuvant therapy should be determined using other clinical indicators such as pGS, SVI, and LNI. For example, high pGS, SVI, and LNI are high-risk factors associated with cancer progression and metastasis, 12 indicating that this subpopulation of patients may achieve improved long-term cancer control outcomes if they are managed using surgery combined with adjuvant hormone therapy. 40, 41 In the present study, patients at intermediate risk of PCa did not routinely undergo immediate ADT after LRP until two consecutive serum PSA values = 0.2 μg l −1 or when symptomatic progression occurred. Further, the chance of progression and the rate of CSM for patients with localized PCa are low, and additional ADT may impair the health of patients and their quality of life. 39 However, the potential risk of tumor progression and metastasis exists in patients with low-or intermediate-risk PCa. [42] [43] [44] A minimum two-point increase in the CAPRA-S score indicates at least a doubling of the risk of recurrence. 12 The establishment of thresholds for assigning CAPRA-S score among low-risk (0-2), intermediate-risk (3) (4) (5) , and high-risk (6) (7) (8) (9) (10) (11) (12) patients should facilitate their use as a risk stratification tool in clinical research. 12 However, most patients with intermediate risk have CAPRA-S score ≤6, whereas the CAPRA-S score alone is insufficient to identify patients at a high risk of poor prognosis. In the present study, CRMP4 methylation levels ≥15% were significantly associated with poor prognosis of the deferred ADT group. The ROC curve indicated that CRMP4 methylation levels had high diagnostic efficiency. Therefore, CRMP4 methylation levels can be used to exclude patients with an increased risk of tumor progression and metastasis, while most were classified with low or intermediate risk of PCa and CAPRA-S score <6.
The frequency of detection of locally advanced PCa is high in China because PSA screening is not universal. 45 Moreover, early hormone therapy administered to selected patients compared with those who did or did not receive hormone therapy after detection of cancer progression will improve the rates of recurrence-free survival and OS. 37, 40, 41, 46 However, the molecular mechanisms of progression and metastasis of locally advanced PCa are unknown. Further, the sensitivities of the conventional methods (e.g., computerized tomography, bone scanning, magnetic resonance imaging, and fluorodeoxyglucose positron emission tomography [47] [48] [49] [50] ) are low for detecting early-stage metastatic cancer. Conventional assessment using the serum PSA level for postoperative BCR requires long-term follow-up. In contrast, CRMP4 methylation levels and CAPRA-S score can be used to quickly assess prognosis after RP. Therefore, the risk assessment model comprising CRMP4 methylation levels and CAPRA-S score makes possible early and convenient assessment of prognosis to guide the selection of optimized timing for adjuvant therapy before disease progression can be detected using standard clinical techniques such as imaging and biochemical analyses.
The limitations of the present study are as follows: first, a relatively small population of patients from a single institution was enrolled, which may introduce selection bias. For example, the CAPRA-S score and CRMP4 methylation levels of patients with intermediate risk in the deferred ADT group were poorly distributed, which may reduce the efficacy of the test. Second, the cutoff value of CRMP4 methylation levels requires further evaluation using larger cohorts from multiple institutions in different countries, which may achieve increased accuracy of evaluating metastatic potential and prognosis. Moreover, longer follow-up will likely improve the efficacy of the assessment of the effects of adjuvant ADT on PFS, CSS, and OS.
CONCLUSIONS
We demonstrated that CRMP4 methylation levels and CAPRA-S score provided improved prognostic value for cancer control in patients who underwent LRP. Thus, combined analysis may be useful for clinicians to design individualized treatment regimens.
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